Finally, we predicted 28 leading edge genes in the IFN pathway associated with ASCL2 expression, which may contribute to revealing the potential mechanism of immune resistance and the management of novel clinical immunotherapy approaches in MSS CRC patients. This evidence concerns the gene IFNA1 and colorectal carcinoma.